The Future of Multiple Myeloma: Pipeline Developments, Personalized Medicine, and Closing Thoughts

In the final episode, 'The Future of Multiple Myeloma: Pipeline Developments, Personalized Medicine, and Closing Thoughts,' the panelists explored the following critical question:

1. As you survey the multiple myeloma pipeline heading into the second half of 2026 and beyond, what developments do you think have the greatest potential to reshape clinical practice in the near term?

Led by the moderator, the panelists examined which pipeline developments hold the greatest potential to reshape multiple myeloma clinical practice in the near term, with particular excitement around CELMoDs as a class poised to replace traditional immunomodulatory agents, offering a stronger immunomodulatory profile, favorable tolerability, and the absence of the long-term MDS risk associated with lenalidomide, while being studied across both frontline and later-line settings in a way that could fundamentally alter the treatment backbone for newly diagnosed and relapsed patients alike. The discussion closed with each panelist sharing their final reflections, with a shared sense of optimism about the field's trajectory. They reflected on how dramatically the myeloma treatment landscape has transformed over the past two decades and looked ahead to a future defined by increasingly individualized treatment decisions. The panelists concluded with a unified vision for the future of myeloma care, one in which the field continues its march toward transforming multiple myeloma into a chronic, manageable disease where patients live longer, better lives and where a cure becomes an increasingly achievable goal.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this Peer Exchange series on multiple myeloma. Please subscribe to our newsletter for information on upcoming video series.